Short Interest in Tema Cardiovascular and Metabolics ETF (NASDAQ:HRTS) Increases By 16.7%

Tema Cardiovascular and Metabolics ETF (NASDAQ:HRTS) saw a large increase in short interest in February. As of February 28th, there was short interest totalling 700 shares, an increase of 16.7% from the February 13th total of 600 shares. Approximately 0.0% of the company’s shares are sold short. Based on an average daily volume of 17,100 shares, the short-interest ratio is presently 0.0 days.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Tema Cardiovascular and Metabolics ETF stock. Sterling Investment Advisors Ltd. boosted its position in Tema Cardiovascular and Metabolics ETF (NASDAQ:HRTS) by 5.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 167,703 shares of the company’s stock after acquiring an additional 9,008 shares during the period. Tema Cardiovascular and Metabolics ETF accounts for about 1.2% of Sterling Investment Advisors Ltd.’s holdings, making the stock its 24th biggest position. Sterling Investment Advisors Ltd. owned approximately 7.29% of Tema Cardiovascular and Metabolics ETF worth $4,842,000 at the end of the most recent reporting period.

Tema Cardiovascular and Metabolics ETF Stock Up 0.2 %

NASDAQ:HRTS traded up $0.06 on Wednesday, hitting $30.05. The stock had a trading volume of 4,155 shares, compared to its average volume of 13,432. The business’s fifty day moving average is $30.01 and its 200 day moving average is $31.62. The company has a market cap of $69.12 million, a PE ratio of 32.63 and a beta of 0.93. Tema Cardiovascular and Metabolics ETF has a 52 week low of $28.56 and a 52 week high of $36.03.

Tema Cardiovascular and Metabolics ETF Company Profile

The Tema Obesity & Cardiometabolic ETF (HRTS) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that concentrates on companies focused on the treatment of cardiovascular diseases and/or metabolic diseases from companies all around the world. Using both top-down and bottom-up stock selection, the fund identifies innovative companies deemed attractive.